$9.30
1.53% today
NYSE, Feb 05, 04:23 pm CET
ISIN
US05380C1027
Symbol
RCEL
Sector

AVITA Therapeutics Stock price

$9.16
-4.49 32.89% 1M
+1.27 16.10% 6M
-3.64 28.44% YTD
-7.55 45.18% 1Y
-0.01 0.11% 3Y
-38.79 80.90% 5Y
+2.51 37.74% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.29 3.27%
ISIN
US05380C1027
Symbol
RCEL
Sector

Key metrics

Market capitalization $227.56m
Enterprise Value $228.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.81
P/S ratio (TTM) P/S ratio 3.79
P/B ratio (TTM) P/B ratio 19.64
Revenue growth (TTM) Revenue growth 32.24%
Revenue (TTM) Revenue $60.04m
EBIT (operating result TTM) EBIT $-137.99m
Free Cash Flow (TTM) Free Cash Flow $-59.91m
Cash position $44.41m
EPS (TTM) EPS $-2.23
P/E forward negative
P/S forward 3.42
EV/Sales forward 3.44
Short interest 6.95%
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a AVITA Therapeutics forecast:

6x Buy
60%
4x Hold
40%

Analyst Opinions

10 Analysts have issued a AVITA Therapeutics forecast:

Buy
60%
Hold
40%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
60 60
32% 32%
100%
- Direct Costs 8.61 8.61
17% 17%
14%
51 51
35% 35%
86%
- Selling and Administrative Expenses 166 166
187% 187%
276%
- Research and Development Expense 22 22
28% 28%
37%
-137 -137
268% 268%
-228%
- Depreciation and Amortization 1.21 1.21
18% 18%
2%
EBIT (Operating Income) EBIT -138 -138
258% 258%
-230%
Net Profit -57 -57
70% 70%
-95%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Negative
Seeking Alpha
24 days ago
AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.
Positive
Seeking Alpha
26 days ago
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
Negative
Reuters
29 days ago
AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target.
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 207
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today